| Serial Number | 99361623 |
| Word Mark | SEED THERAPEUTICS |
| Filing Date | Wednesday, August 27, 2025 |
| Status | 680 - APPROVED FOR PUBLICATION |
| Status Date | Wednesday, July 1, 2026 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | NOT AVAILABLE |
| NOT AVAILABLE | "THERAPEUTICS" |
| Goods and Services | Drug discovery and pharmaceutical drug development services; Drug validation services, namely, scientifically demonstrating that a new molecular entity has the potential to achieve, or achieves an acceptable balance of benefit to the patients versus side effects; Pharmaceutical research and development; providing medical research and scientific information in the fields of pharmaceuticals, biology, chemistry, biochemistry, biotechnology, and clinical trials; providing scientific, pharmaceutical, clinical research and medical research information about pharmaceutical drug development via the internet; consulting services in the fields of pharmaceuticals research, biology research, chemistry, biochemistry, scientific biotechnology research, and design, planning, and implementation of clinical trials; research and development of new products; scientific, research and development services; medical research services; Providing information about medical and scientific research relating to the identification of ubiquitin ligases for the purposes of degrading a disease-causing protein; scientific consultancy services in the field of identifying ubiquitin ligases for the purposes of degrading a disease-causing protein; Providing information about medical and scientific research with respect to using a photocatalyst molecule for labeling a protein proximate to a target disease-causing protein within a live cell; scientific consultancy services in the field of using a photocatalyst molecule for labeling a protein proximate to a target disease-causing protein within a live cell |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, August 27, 2025 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | SEED Therapeutics US, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | King of Prussia, PA 19406 US |
| Event Date | Event Description |
| Wednesday, August 27, 2025 | NEW APPLICATION ENTERED |
| Wednesday, August 27, 2025 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Wednesday, August 27, 2025 | APPLICATION FILING RECEIPT MAILED |
| Tuesday, January 13, 2026 | ASSIGNED TO EXAMINER |
| Wednesday, January 21, 2026 | NON-FINAL ACTION WRITTEN |
| Wednesday, January 21, 2026 | NON-FINAL ACTION E-MAILED |
| Wednesday, January 21, 2026 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Monday, April 20, 2026 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
| Monday, April 20, 2026 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
| Friday, April 24, 2026 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Friday, April 24, 2026 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Friday, April 24, 2026 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, May 21, 2026 | FINAL REFUSAL WRITTEN |
| Thursday, May 21, 2026 | FINAL REFUSAL E-MAILED |
| Thursday, May 21, 2026 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Monday, June 22, 2026 | EXAMINERS AMENDMENT -WRITTEN |
| Monday, June 22, 2026 | EXAMINERS AMENDMENT E-MAILED |
| Monday, June 22, 2026 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Tuesday, June 23, 2026 | ASSIGNED TO LIE |
| Wednesday, June 24, 2026 | EXAMINER'S AMENDMENT ENTERED |
| Wednesday, July 1, 2026 | APPROVED FOR PUB - PRINCIPAL REGISTER |